Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a Glibenclamide (cas 10238-21-8)-induced canine hypoglycaemia model

Add time:07/29/2019    Source:sciencedirect.com

The commonly used sedative α2-adrenoceptor agonist dexmedetomidine has adverse cardiovascular effects in dogs that can be prevented by concomitant administration of the peripherally acting α2-adrenoceptor antagonist MK-467. An ancillary effect of dexmedetomidine is to decrease insulin release from the pancreas, whereas MK-467 stimulates insulin release. This study assessed the effects of co-administered dexmedetomidine and MK-467 in a canine glibenclamide-induced hypoglycaemia model. In a randomised, cross-over experiment, eight beagle dogs received five intravenous treatments, comprising two administrations of saline, with dexmedetomidine or dexmedetomidine and MK-467, and three administrations of glibenclamide, with saline, dexmedetomidine or dexmedetomidine and MK-467. Plasma concentrations of glucose, lactate, insulin, glucagon and the test drugs were monitored. Administration of glibenclamide significantly increased insulin secretion and decreased blood glucose concentrations. Dexmedetomidine counteracted glibenclamide-evoked hypoglycaemia. This was opposed by the α2-adrenoceptor antagonist MK-467, but the glibenclamide-evoked hypoglycaemia was not potentiated by co-administration of dexmedetomidine and MK-467. None of the dogs developed uncontrolled hypoglycaemia. Thus, the combination of dexmedetomidine and MK-467 appeared to be safe in this canine hypoglycaemia model. Nevertheless, when MK-467 is used to alleviate the undesired cardiovascular effects of α2-adrenoceptor agonists in dogs, it should be used with caution in animals at risk for hypoglycaemia because of its insulin-releasing and hypoglycaemic effects.

We also recommend Trading Suppliers and Manufacturers of Glibenclamide (cas 10238-21-8). Pls Click Website Link as below: cas 10238-21-8 suppliers

Prev:Peceosomes for oral delivery of Glibenclamide (cas 10238-21-8): In vitro in situ correlation
Next:Controlled release of Glibenclamide (cas 10238-21-8) from monolithic silica subdermal implants produced by the sol-gel process and its use for hyperglycaemia treatment in a murine model)